secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcus Biosciences, Inc. (RCUS)
CIK:        0001724521
Form:       8-K
Filed at:   2025-02-18T23:59:59+00:00
Accession:  0001193125-25-028110
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcus reports $992M cash; Gilead opts out of casdatifan; ARC-20 data shows ORR 25-33%
--------------------------------------------------------------------------------

- Preliminary cash, cash equivalents and marketable securities of $992M as of Dec 31, 2024.
- Gilead's exclusive option for casdatifan expired without exercise; Arcus retains full global rights.
- ARC-20 in ccRCC: 50mg BID median PFS 9.7 months, ORR 25%; 100mg QD ORR 33%.
- Disease control rate 81-87% across cohorts; median DoR not reached; safety acceptable.
- All but two of 26 responders remained on treatment; one discontinuation due to anemia.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1724521/000119312525028110/0001193125-25-028110-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1724521/000119312525028110/d901841d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-028110

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer